The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis

TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis

November 22, 2016 • By Lorraine L. Janeczko

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Psoriasis patients treated with tumor necrosis factor-alpha (TNF) inhibitors may have a lower risk of major cardiovascular (CV) events than those treated with methotrexate (MTX), according to a new study.

You Might Also Like
  • For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Psoriasis Tied to Higher Risk of Serious Liver Disease

“The findings do not surprise me. TNF inhibitors control inflammation better than methotrexate,” lead author Dr. Jashin J. Wu of Kaiser Permanente Los Angeles Medical Center in Calif. tells Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The findings were published online on Oct. 26 in the Journal of the American Academy of Dermatology.

Using data from Truven MarketScan Database, Dr. Wu and his colleagues classified adult psoriasis patients who had two or more TNF inhibitors or MTX prescriptions as either TNF inhibitors or MTX users.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At 12 months, the 9,148 TNF inhibitor users had fewer CV events than the 8,581 MTX users (Kaplan-Meier rates: 1.45% vs. 4.09%: p<0.01). Over a median follow up of 24 months, every six-month period of cumulative exposure to TNF inhibitors was associated with an 11% drop in CV event risk (p=0.02).

Co-author and data analyst Annie Guerin, vice president at Analysis Group in Boston, tells Reuters Health by email, “The impact of psoriasis treatment goes beyond the management of skin symptoms. In this study, TNF inhibitors were associated with a reduced risk of cardiovascular events, and cumulative exposure to TNF inhibitors resulted in an incremental cardiovascular event risk reduction. When making treatment decisions, the concurrent reduction in cardiovascular risk should be considered.”

“It was important to do this study to see if treating patients with TNF inhibitors improves more than just psoriasis,” Dr. Wu says. “Perhaps TNF inhibitors should be prescribed first, ahead of MTX, although many health plans require that patients fail methotrexate first.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The authors acknowledged that the lack of clinical assessment measures was a limitation of their study.

“Further studies are warranted to compare the cardiovascular risk among other treatment options for psoriasis,” Ms. Guerin says.

Dr. Wu agreed, explaining that he would like to explore whether other biologics for psoriasis also improve major adverse cardiovascular events.

AbbVie helped design, conduct and fund the study. Dr. Wu is a consultant for the drugmaker, and two of his co-authors are employees at AbbVie.


Reference

  1. Wu JJ, Guérin A, Sundaram M. et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2016 Oct 26. doi: http://dx.doi.org/10.1016/j.jaad.2016.07.042

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: cardiovascular, heart, metho­trexate, Psoriasis, TNF, TNF inhibitor

You Might Also Like:
  • For Psoriasis, Ustekinumab & TNF Inhibitors Show Similar Cardiac Safety
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Psoriasis Tied to Higher Risk of Serious Liver Disease
  • Psoriasis Tied to Increased Risk of Major Depression

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.